Neuroscience
FDA approves new multiple sclerosis treatment: Tecfidera
27 March 2013
- Fda: Generic Lexapro
A press release from the FDA: FDA approves first generic Lexapro to treat depression and anxiety disorder 14 March 2012 Read the full press release...
- Multiple Sclerosis (ms): The Surpass Clinical Trial
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS): ClinicalTrials.gov Description === Corporate press release ===...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...
Neuroscience
FDA approves new multiple sclerosis treatment: Tecfidera
FDA approves new multiple sclerosis treatment: Tecfidera
27 March 2013
Resd the press release
- Fda: Generic Lexapro
A press release from the FDA: FDA approves first generic Lexapro to treat depression and anxiety disorder 14 March 2012 Read the full press release...
- Multiple Sclerosis (ms): The Surpass Clinical Trial
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS): ClinicalTrials.gov Description === Corporate press release ===...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...